Literature DB >> 28677896

Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

Nam H Dang1, Michinori Ogura2,3, Sylvie Castaigne4, Luis E Fayad5, Mats Jerkeman6, John Radford7, Antonio Pezzutto8, Igor Bondarenko9, Douglas A Stewart10, Michael Shnaidman11, Sharon Sullivan11, Erik Vandendries11, Kensei Tobinai12, Radhakrishnan Ramchandren13, Paul A Hamlin14, Eva Giné15, Kiyoshi Ando16.   

Abstract

Entities:  

Keywords:  B-cell non-Hodgkin lymphoma; CD22+; antibody-drug conjugate; inotuzumab ozogamicin; rituximab

Mesh：

Substances：

Year:  2017        PMID： 28677896      PMCID： PMC6200343          DOI： 10.1111/bjh.14820

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  5 in total

1.  Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma.

Authors:  Michinori Ogura; Kensei Tobinai; Kiyohiko Hatake; Andrew Davies; Michael Crump; Revathi Ananthakrishnan; Taro Ishibashi; M Luisa Paccagnella; Joseph Boni; Erik Vandendries; David MacDonald
Journal:  Clin Cancer Res       Date:  2016-05-06       Impact factor: 12.531

2.  Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.

Authors:  Luis Fayad; Fritz Offner; Mitchell R Smith; Gregor Verhoef; Peter Johnson; Jonathan L Kaufman; Ama Rohatiner; Anjali Advani; James Foran; Georg Hess; Bertrand Coiffier; Myron Czuczman; Eva Giné; Simon Durrant; Michelle Kneissl; Kenneth T Luu; Steven Y Hua; Joseph Boni; Erik Vandendries; Nam H Dang
Journal:  J Clin Oncol       Date:  2013-01-07       Impact factor: 44.544

3.  Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma.

Authors:  Michinori Ogura; Kiyohiko Hatake; Kiyoshi Ando; Kensei Tobinai; Kota Tokushige; Chiho Ono; Taro Ishibashi; Erik Vandendries
Journal:  Cancer Sci       Date:  2012-03-20       Impact factor: 6.716

4.  Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.

Authors:  Anjali Advani; Bertrand Coiffier; Myron S Czuczman; Martin Dreyling; James Foran; Eva Gine; Christian Gisselbrecht; Nicolas Ketterer; Sunita Nasta; Ama Rohatiner; Ingo G H Schmidt-Wolf; Martin Schuler; Jorge Sierra; Mitchell R Smith; Gregor Verhoef; Jane N Winter; Joseph Boni; Erik Vandendries; Mark Shapiro; Luis Fayad
Journal:  J Clin Oncol       Date:  2010-03-22       Impact factor: 44.544

5.  Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy.

Authors:  Michinori Ogura; Kensei Tobinai; Kiyohiko Hatake; Toshiki Uchida; Masanobu Kasai; Takashi Oyama; Tatsuya Suzuki; Yukio Kobayashi; Takashi Watanabe; Teruhisa Azuma; Masakazu Mori; Yasuhito Terui; Masahiro Yokoyama; Yuko Mishima; Shunji Takahashi; Chiho Ono; Junko Ohata
Journal:  Cancer Sci       Date:  2010-04-23       Impact factor: 6.716
  5 in total
  19 in total

Review 1.  Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia.

Authors:  Joseph Wynne; David Wright; Wendy Stock
Journal:  Blood Adv       Date:  2019-01-08

Review 2.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

Review 3.  Immunotherapy of lymphomas.

Authors:  Stephen M Ansell; Yi Lin
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

4.  Liver Complications Following Treatment of Hematologic Malignancy With Anti-CD22-Calicheamicin (Inotuzumab Ozogamicin).

Authors:  George B McDonald; James W Freston; James L Boyer; Laurie D DeLeve
Journal:  Hepatology       Date:  2019-01-18       Impact factor: 17.425

Review 5.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

Review 6.  Antibody-Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review.

Authors:  Cédric Rossi; Marie-Lorraine Chrétien; René-Olivier Casasnovas
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

Review 7.  Advances in Immunotherapy for Diffuse Large B Cell Lymphoma.

Authors:  Geoffrey Shouse; Alex F Herrera
Journal:  BioDrugs       Date:  2021-07-15       Impact factor: 5.807

Review 8.  Combining Biology and Chemistry for a New Take on Chemotherapy: Antibody-Drug Conjugates in Hematologic Malignancies.

Authors:  Helen Ma; Ahmed Sawas
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

Review 9.  Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress.

Authors:  Yurou Chu; Xiangxiang Zhou; Xin Wang
Journal:  J Hematol Oncol       Date:  2021-06-05       Impact factor: 17.388

Review 10.  Stepping forward in antibody-drug conjugate development.

Authors:  Yiming Jin; Megan A Schladetsch; Xueting Huang; Marcy J Balunas; Andrew J Wiemer
Journal:  Pharmacol Ther       Date:  2021-06-24       Impact factor: 12.310
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.